Drugs / ASP4396
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06364696 | Apr 2024 → Jun 2026 | cancer | Astellas Pharma Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP4396 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06364696 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT06364696 ↗ |